HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

atorvastatin drug combination amlodipine

Also Known As:
amlodipine, atorvastatin drug combination; Caduet; Pfizer brand of amlodipine, atorvastatin drug combination; amlodipine - atorvastatin
Networked: 33 relevant articles (2 outcomes, 12 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Sutradhar, Santosh: 7 articles (01/2014 - 01/2009)
2. Yunis, Carla: 6 articles (01/2014 - 01/2009)
3. Zamorano, José: 4 articles (06/2013 - 04/2011)
4. Kim, Jae-Hyung: 3 articles (05/2013 - 04/2011)
5. Al-Khadra, Ayman: 3 articles (05/2013 - 04/2011)
6. Pavia, Abel: 3 articles (05/2013 - 04/2011)
7. Erdine, Serap: 3 articles (05/2013 - 04/2011)
8. Kursun, Attila: 3 articles (01/2010 - 01/2009)
9. Genest, Jacques: 3 articles (08/2009 - 01/2005)
10. Westergaard, Mogens: 2 articles (01/2014 - 04/2011)

Related Diseases

1. Hypertension (High Blood Pressure)
2. Coronary Disease (Coronary Heart Disease)
04/01/2011 - "To investigate whether a proactive multifactorial risk factor intervention strategy using single-pill amlodipine/atorvastatin (5/10, 10/10 mg) in addition to other antihypertensive and lipid-lowering therapy, as required, resulted in greater reduction in calculated Framingham 10-year coronary heart disease (CHD) risk compared with usual care (UC) after 52-weeks treatment. "
01/15/2005 - "Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease."
01/01/2013 - "In the phase 2 study, patients with treated but uncontrolled hypertension and three or more coronary heart disease risk factors received single-pill amlodipine/atorvastatin (5/10 or 10/10 mg) for 12 weeks. "
05/01/2013 - "To compare the reduction in calculated Framingham 10 year coronary heart disease (CHD) risk after 52 weeks' intervention with a proactive multifactorial intervention (PMI) strategy (based on single-pill amlodipine/atorvastatin [SPAA]) versus continuing usual care (UC) (based on investigators' best clinical judgment) among younger (<65 years) and older (≥ 65 years) patients. "
06/01/2013 - "A proactive, multifactorial intervention strategy incorporating single-pill amlodipine/atorvastatin (SPAA) (5-10/10 mg up-titrated to 5-10/20 mg, where approved) is more effective than physician's usual care (UC) for reducing calculated 10 year coronary heart disease (CHD) risk, in patients with hypertension and additional risk factors (CRUCIAL trial: Curr Med Res Opin 2011;27:821--33). "
3. Dyslipidemias (Dyslipidemia)
4. Cardiovascular Diseases (Cardiovascular Disease)
5. Insulin Resistance

Related Drugs and Biologics

1. spiropentaneacetic acid (SPAA)
2. atorvastatin drug combination amlodipine
3. LDL Cholesterol
4. Amlodipine (Norvasc)
5. atorvastatin (Lipitor)
6. Cholesterol
7. Calcium Channels (Calcium Channel)
8. Plasminogen Activators (Plasminogen Activator)
9. Tissue Plasminogen Activator (Alteplase)
10. Adenosine Triphosphate (ATP)

Related Therapies and Procedures

1. Aftercare (After-Treatment)